Allogene Therapeutics, Inc.
ALLO
$1.78
-$0.08-4.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 16.23% | 28.67% | 35.25% | 37.55% | 23.23% |
| Total Depreciation and Amortization | -14.84% | -7.42% | -5.44% | -3.43% | -14.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.48% | -29.54% | -43.30% | -64.97% | -36.94% |
| Change in Net Operating Assets | 120.97% | 321.50% | -103.83% | 97.60% | 87.84% |
| Cash from Operations | 18.02% | 75.60% | 24.79% | 32.70% | 38.62% |
| Capital Expenditure | -240.91% | 90.91% | 100.00% | 43.36% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -435.94% | -571.38% | -39.10% | 116.12% | -41.19% |
| Cash from Investing | -436.62% | -579.08% | -38.81% | 115.71% | -41.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12,308.98% | 98.52% | 36.84% | 376.58% | -98.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 56.05% |
| Cash from Financing | 3,604.10% | 50.98% | 36.84% | 376.58% | -95.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.79% | 34.75% | -42.15% | 87.84% | -91.74% |